Home Executive-Insights CCO Beth Marsh Named as Chief Comm...

Beth Marsh Named as Chief Commercial Officer at Neurotech Pharmaceuticals

CCO

Business Honor
21 April, 2025

Beth Marsh joins Neurotech to lead ENCELTO's launch, bringing deep ophthalmology commercial expertise.

Neurotech Pharmaceuticals, Inc., a private biotech company that is advancing treatments for chronic eye diseases, has appointed Beth Marsh as Chief Commercial Officer, effective April 28, 2025. Marsh will lead the company’s commercial strategy as the company prepares for the first and only approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel), ENCELTOTM will be introduced in the United States and should be accessible in June.

Marsh has more than 20 years of experience in ophthalmology and retina as a commercial and strategic leader. She most recently led the commercial introduction of SYFOVRE®, the first licensed treatment for geographic atrophy owing to AMD, in the United States while she was VP of North America Sales and Marketing in Ophthalmology at Apellis Pharmaceuticals. Additionally, she was a commercial leader at Johnson & Johnson Vision Care, Aciex Therapeutics, Shire/Takeda, and Santen.

Richard Small, CEO of Neurotech, expressed interest about Beth Marsh joining the company at such a critical juncture, highlighting her successful history in launching retinal disease therapies and her robust industry network as one of the most important resources for guaranteeing ENCELTO's successful launch.

Beth Marsh shared her interest about joining Neurotech at a change in time, expressing eagerness to partnership with the company’s talented team to bring ENCELTO to patients and help reshape the treatment landscape for MacTel. Marsh holds a B.S. degree in business administration from Miami University and has been an OWL president and nonprofit leader: Promoting Diversity in Ophthalmology Leadership.

Neurotech is in a strong position to provide its groundbreaking treatment to patients in need, with Marsh leading the commercialization effort.